10-Q: DiaMedica Appoints New CMO, Reports Mixed Q3 Results

DiaMedica Therapeutics appoints Dr. Julie Krop as Chief Medical Officer, reports increased net loss and cash burn, but positive interim PE trial data and successful capital raise.

Summary

• DiaMedica Therapeutics Inc. appointed Julie Krop, MD, as Chief Medical Officer, effective August 11, 2025, with an annual base salary of $525,000 and a 40% target bonus.
• The company reported a net loss of $24.0 million for the nine months ended September 30, 2025, compared to $16.5 million for the same period in 2024.
• Cash, cash equivalents, and marketable securities increased to $55.3 million as of September 30, 2025, from $44.1 million at December 31, 2024.
• Research and development expenses rose to $17.9 million for the nine months ended September 30, 2025, up from $12.6 million in the prior year, driven by clinical trial activities.
• General and administrative expenses increased to $7.3 million for the nine months ended September 30, 2025, from $5.7 million in 2024, due to personnel costs and professional fees.
• Interim results from the Phase 2 PE trial (N=28 subjects) in July 2025 showed DM199 to be safe, well-tolerated, with clinically-relevant pharmacodynamic activity, no placental transfer, and significant blood pressure reductions.
• The Phase 2/3 ReMEDy2 trial for Acute Ischemic Stroke (AIS) continues to experience slower than expected site activations and enrollment due to various factors, including staffing shortages and competition.
• DiaMedica successfully raised approximately $30.0 million in net proceeds from a private placement in July 2025.
• The company entered into an At-The-Market (ATM) offering program on August 12, 2025, to sell up to $100 million in common shares, with $98.4 million remaining available as of September 30, 2025.
• A legal dispute with ICON/PRA Netherlands regarding clinical study data was settled on October 31, 2025, through a mutual release agreement.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While financial losses and AIS trial delays are concerning, the successful capital raise, extended cash runway, positive interim PE trial data, and resolution of a legal dispute provide significant positive momentum and stability for a clinical-stage company.

Positives

• Appointment of Julie Krop, MD, as Chief Medical Officer, a key leadership role for clinical development.
• Positive interim results from the Phase 2 PE trial, demonstrating DM199's safety, tolerability, pharmacodynamic activity, and significant blood pressure reduction without placental transfer.
• Successful completion of a private placement in July 2025, raising $30.0 million in net proceeds, strengthening the company's cash position.
• Increased cash, cash equivalents, and marketable securities to $55.3 million, providing a projected runway of at least 12 months.
• Resolution of the legal dispute with ICON/PRA Netherlands through a settlement agreement, removing a potential legal overhang.

Negatives

• Increased net loss to $24.0 million for the nine months ended September 30, 2025, compared to $16.5 million in the prior year.
• Higher cash used in operating activities, increasing to $21.3 million for the nine months ended September 30, 2025, from $15.6 million in 2024.
• Slower than expected site activations and enrollment in the Phase 2/3 ReMEDy2 trial for AIS, potentially delaying key milestones.
• Decreased other income, net, due to lower average marketable securities balances, impacting overall financial performance.
• Ongoing challenges in the ReMEDy2 trial, including hospital staffing shortages, strict inclusion/exclusion criteria, and competition from other neurological trials.

Risks

• Future clinical trials may fail to replicate promising data seen in earlier preclinical studies and interim clinical trials, potentially hindering regulatory approval.
• Failure to meet primary or secondary endpoints in ongoing or future trials, or receiving a restricted product label, could negatively impact commercialization.
• Changes in funding and staffing for regulatory agencies like the FDA and SEC could delay product development, approval, or commercialization.
• The company will require substantial additional capital to complete R&D activities, clinical studies, and regulatory processes, with no assurance of obtaining favorable financing terms.
• The adaptive design of the ReMEDy2 trial means the final sample size could range from 300 to 728 patients, introducing uncertainty in trial duration and cost.
• Reliance on physician collaborators for the PE study introduces dependency on external parties for study conduct.

Future Outlook

The company expects operating losses to moderately increase in future periods as it expands its PE clinical development program and continues the global expansion of its ReMEDy2 trial. Current cash resources are projected to fund planned operations for at least the next 12 months, but substantial additional capital will be required to complete R&D activities and achieve regulatory approvals. The interim analysis for the ReMEDy2 trial is estimated to be completed in the second half of 2026.

Management Comments

• We expect to continue to incur substantial operating losses until such time as any future product sales, licensing fees, milestone payments and/or royalty payments generate revenue sufficient to fund our continuing operations.
• We expect our current cash, cash equivalents and marketable securities to be sufficient to continue the Phase 2 PE trial, the ReMEDy2 trial and otherwise fund our planned operations for at least the next 12 months from the date of issuance of these condensed consolidated financial statements.
• We intend to continue to monitor the results of these efforts [to mitigate ReMEDy2 delays] and, if necessary, implement additional actions to enhance site activations and enrollment in our ReMEDy2 trial; however, no assurances can be provided as to the success of these actions and if or when these issues will resolve.

Industry Context

DiaMedica operates in the highly competitive and regulated biopharmaceutical industry, focusing on severe ischemic diseases like preeclampsia and acute ischemic stroke. The challenges faced in the ReMEDy2 trial, such as hospital staffing shortages and competition for research staff, reflect broader industry-wide issues impacting clinical trial execution, particularly in complex neurological indications. The positive interim data for DM199 in preeclampsia, a condition with no approved treatments, positions the company uniquely in a high-unmet-need area, potentially offering a significant advantage if further trials are successful and regulatory approval is obtained. The company's strategy to expand globally for its AIS trial is a common approach for biopharma companies seeking to accelerate enrollment and diversify trial sites.

Comparison to Industry Standards

• NA The filing primarily focuses on internal operational and clinical trial updates, and a new executive appointment, rather than direct comparisons to specific industry benchmarks or competitor results. The company is in a clinical stage, making direct commercial comparisons less relevant at this point.

Management Changes

Corporate Governance

Legal Proceedings

• A legal dispute with Pharmaceutical Research Associates Group B.V. and PRA Health Sciences, Inc. (ICON/PRA Netherlands) regarding clinical study documents and data was settled on October 31, 2025.
• The settlement involved a mutual release agreement to resolve all disputes, claims, and liabilities, and DiaMedica agreed to release certain data held by a judicial custodian.
• No other material pending legal proceedings are reported.

Related Party Transactions

• NA No specific related party transactions were disclosed in the filing beyond standard executive compensation and equity awards.

Stakeholder Impact

• **Shareholders:** Experience dilution from recent equity raises but benefit from a strengthened cash position and continued funding for clinical trials. Positive PE data could increase long-term value, while AIS trial delays introduce uncertainty.
• **Employees:** The appointment of a new CMO and expansion of the clinical team indicate growth and investment in human capital. Equity incentive plans provide motivation.
• **Customers/Patients:** Potential future beneficiaries of DM199 for preeclampsia and acute ischemic stroke, if trials are successful and regulatory approvals are obtained. Delays in AIS trial enrollment mean a longer wait for potential treatment options.
• **Creditors/Suppliers:** Improved liquidity from capital raises enhances the company's ability to meet its financial obligations to vendors and other creditors.
• **Regulatory Bodies:** The company is actively engaging with the FDA (pre-IND meeting for PE) and other international regulatory bodies (UK approval for ReMEDy2), indicating ongoing compliance and progress in regulatory pathways.

Next Steps

• Initiate Part 1b of the Phase 2 PE trial, treating up to 30 subjects with PE using a dose regimen identified from Part 1a.
• Continue efforts to mitigate slower site activations and enrollment in the ReMEDy2 trial, including global expansion and potential additional protocol changes.
• Complete regulatory filings and engage study sites in an additional seven European countries for the ReMEDy2 trial.
• Receive and provide an update on the final meeting minutes from the pre-IND meeting with the FDA regarding the PE program.
• Complete the interim analysis for the ReMEDy2 trial, estimated for the second half of 2026.

Key Dates

Recommendation

DiaMedica is a clinical-stage biopharmaceutical company with high risk and high reward potential. The positive interim data from the Phase 2 PE trial is a significant positive, addressing a high unmet medical need. However, the increased net loss and cash burn, coupled with persistent and significant delays in the larger Phase 2/3 AIS trial, introduce considerable uncertainty and extend the timeline to potential commercialization. While the recent capital raise provides a 12-month cash runway, substantial additional funding will be required. The appointment of a new CMO is a positive leadership development. Given the mixed clinical news, the ongoing need for capital, and the inherent volatility of clinical-stage biotech, a 'hold' recommendation is appropriate for investors who are already positioned, awaiting further clarity on the AIS trial progress and future PE development. New investors should approach with caution, recognizing the high-risk, high-reward profile.

Keywords

DiaMedica Therapeutics, DMAC, Chief Medical Officer, Julie Krop, Preeclampsia, Acute Ischemic Stroke, DM199, ReMEDy2 trial, Clinical trial delays, Biopharmaceutical, SEC 10-Q, Financial results, Capital raise, Clinical stage, Kallikrein-1, Corporate governance